Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Costello AJ. Considering the role of radical prostatectomy in 21st century Prostate cancer care. Nat Rev Urol. 2020;17(3):177–88.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, Surgery, or Radiotherapy for localized Prostate Cancer. N Engl J Med. 2016;375(15):1415–24.
Bekelman JE, Rumble RB, Freedland SJ. Clinically localized Prostate Cancer: ASCO Clinical Practice Guideline endorsement of an AUA/ASTRO/SUO Guideline Summary. J Oncol Pract. 2018;14(10):618–24.
Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O. Risk of postoperative up staging or upgrading among men with low risk familial Prostate Cancer. J Urol. 2020;204(1):79–81.
Maurice MJ, Sundi D, Schaeffer EM, Abouassaly R. Risk of pathological upgrading and up staging among men with low risk Prostate Cancer varies by race: results from the National Cancer Database. J Urol. 2017;197(3 Pt 1):627–31.
Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25(2):110–4.
Morizane S, Yumioka T, Makishima K, Tsounapi P, Iwamoto H, Hikita K, et al. Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomy. Int J Clin Oncol. 2021;26(10):1961–7.
Martini A, Gandaglia G, Fossati N, Scuderi S, Bravi CA, Mazzone E, et al. Defining clinically meaningful positive Surgical margins in patients undergoing radical prostatectomy for localised Prostate Cancer. Eur Urol Oncol. 2021;4(1):42–8.
Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk Prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23(4):429–36.
Gietelink L, Jansen BHE, Oprea-Lager DE, Nieuwenhuijzen JA, Vis AN. Preoperative multiparametric MRI does not lower positive surgical margin rate in a large series of patients undergoing robot-assisted radical prostatectomy. J Robot Surg. 2022;16(2):273–8.
Kozikowski M, Malewski W, Michalak W, Dobruch J. Clinical utility of MRI in the decision-making process before radical prostatectomy: systematic review and meta-analysis. PLoS ONE. 2019;14(1):e0210194.
Jäderling F, Akre O, Aly M, Björklund J, Olsson M, Adding C, et al. Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after Prostate-cancer Surgery. Prostate Cancer Prostatic Dis. 2019;22(3):391–8.
Haug ES, Myklebust T, Juliebø-Jones P, Reisæter LAR, Aas K, Berg AS, et al. Impact of prebiopsy MRI on Prostate cancer staging: results from the Norwegian Prostate Cancer Registry. BJUI Compass. 2023;4(3):331–8.
Costa DN, Meng X, Tverye A, Bagrodia A, Recchimuzzi DZ, Xi Y, et al. Preoperative multiparametric prostate magnetic resonance imaging structured Report informs risk for positive apical Surgical margins during Radical Prostatectomy. J Comput Assist Tomogr. 2023;47(1):38–44.
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22(4):746–57.
Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Eur Urol. 2019;76(3):340–51. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.
Benidir T, Lone Z, Wood A, Abdallah N, Campbell R, Bajic P et al. Using IsoPSA with PI-RADS score may help refine Biopsy decision making in patients with elevated PSA. Urology. 2023.
Xu L, Zhang G, Zhang D, Zhang X, Bai X, Yan W, et al. Comparison of PI-RADS version 2.1 and PI-RADS version 2 regarding interreader variability and diagnostic accuracy for transition zone Prostate cancer. Abdom Radiol (NY). 2020;45(12):4133–41.
Tamada T, Sone T, Kanomata N, Miyaji Y, Kido A, Jo Y, et al. Value of preoperative 3T multiparametric MRI for surgical margin status in patients with Prostate cancer. J Magn Reson Imaging. 2016;44(3):584–93.
Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228-42.
Raeside M, Low A, Cohen P, Sutherland P, Gormly K. Prostate MRI evolution in clinical practice: audit of tumour detection and staging versus prostatectomy with staged introduction of multiparametric MRI and prostate imaging reporting and Data System v2 reporting. J Med Imaging Radiat Oncol. 2019;63(4):487–94.
Greer MD, Brown AM, Shih JH, Summers RM, Marko J, Law YM, et al. Accuracy and agreement of PIRADSv2 for Prostate cancer mpMRI: a multireader study. J Magn Reson Imaging. 2017;45(2):579–85.
Gatti M, Faletti R, Gentile F, Soncin E, Calleris G, Fornari A, et al. mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of Prostate cancer at multiparametric magnetic resonance imaging. Eur Radiol. 2022;32(7):4942–53.
Gilliland FD, Hoffman RM, Hamilton A, Albertsen P, Eley JW, Harlan L, et al. Predicting extracapsular extension of Prostate cancer in men treated with radical prostatectomy: results from the population based Prostate cancer outcomes study. J Urol. 1999;162(4):1341–5.
Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with Prostate cancer. JAMA. 1999;281(15):1395–400.
Patel HD, Okabe Y, Rac G, Pahouja G, Desai S, Shea SM, et al. MRI versus non-MRI diagnostic pathways before radical prostatectomy: impact on nerve-sparing, positive surgical margins, and biochemical recurrence. Urol Oncol. 2023;41(2):104.e19–.e27.
Add Comment